海正药业(600267) - 2019 Q3 - 季度财报
HISUNHISUN(SH:600267)2019-10-30 16:00

Financial Performance - Operating income for the first nine months rose by 6.50% to CNY 8,311,704,808.14 compared to the same period last year[18]. - Net profit attributable to shareholders surged to CNY 1,254,988,330.54, a significant increase of 17,541.98% compared to the previous year[18]. - Basic earnings per share increased to CNY 1.300, up 18,471.43% compared to the previous year[21]. - The weighted average return on net assets rose to 15.675%, an increase of 15.569 percentage points[21]. - Total operating revenue for Q3 2019 reached ¥2,646,050,151.54, an increase of 7% compared to ¥2,473,273,802.29 in Q3 2018[65]. - Year-to-date operating revenue for the first three quarters of 2019 was ¥8,311,704,808.14, up 6.5% from ¥7,804,691,797.38 in the same period of 2018[65]. - The company reported a total profit for the quarter of ¥1,288,839,300.76, a significant rise from ¥30,432,487.27 in the same quarter last year[74]. - Net profit for the quarter was ¥1,242,780,521.30, compared to ¥24,838,042.92 in the same quarter last year, indicating a substantial increase[74]. - The company reported a total cash inflow from financing activities of CNY 8,636,130,336.03, compared to CNY 6,328,730,475.08 in the previous period, marking a growth of 36.4%[95]. Assets and Liabilities - Total assets increased by 12.53% to CNY 24,592,135,696.73 compared to the end of the previous year[18]. - Net assets attributable to shareholders increased by 20.29% to CNY 7,438,353,404.92 compared to the end of the previous year[18]. - The company's total liabilities reached RMB 15.78 billion as of September 30, 2019, compared to RMB 14.48 billion at the end of 2018[55]. - The company reported a short-term loan of RMB 5.91 billion as of September 30, 2019, an increase from RMB 5.68 billion at the end of 2018[55]. - The company’s long-term borrowings decreased to RMB 2.05 billion as of September 30, 2019, from RMB 2.52 billion at the end of 2018[55]. - The company reported a total liability of approximately ¥14.48 billion, with current liabilities at ¥9.56 billion and non-current liabilities at ¥4.92 billion[104]. - The company has short-term borrowings of approximately ¥5.68 billion, reflecting its financing strategy[104]. - The company has long-term borrowings of approximately ¥2.52 billion, indicating reliance on debt financing for growth[104]. Cash Flow - Net cash flow from operating activities decreased by 36.19% to CNY 613,635,459.47 compared to the same period last year[18]. - Cash flow from operating activities for the first three quarters of 2019 was ¥7.95 billion, an increase from ¥7.13 billion in the same period of 2018[89]. - The net cash flow from operating activities was CNY 613,635,459.47, a decrease of 36.1% compared to CNY 961,728,533.85 in the previous period[93]. - Total cash inflow from investment activities was CNY 1,622,696,377.69, an increase of 53.6% from CNY 1,055,263,273.91[93]. - Cash outflow for investment activities totaled CNY 2,206,414,518.97, an increase of 31.4% from CNY 1,677,198,047.83[93]. - The company paid CNY 686,828,329.67 in taxes, an increase of 41.1% from CNY 486,386,385.16 in the previous period[93]. Shareholder Information - The total number of shareholders at the end of the reporting period was 37,363[27]. - The largest shareholder, Zhejiang Haizheng Group, holds 33.22% of the shares[27]. Investments and R&D - Research and development expenses grew by 46.83% to ¥440,226,295.90, reflecting increased investment in ongoing R&D projects[39]. - Long-term equity investments rose by 292.17% to ¥1,301,765,564.91, reflecting the remaining equity held in Haizheng Borui[33]. - The company plans to expand its market presence and enhance R&D capabilities through strategic partnerships and investments[42]. - Investment income increased by 3642.12% to ¥1,602,434,725.44, attributed to gains from the sale of part of Borui's equity[39]. Other Financial Metrics - The company reported a loss of CNY 403,949,319.90 attributable to non-recurring gains and losses[18]. - Accounts receivable increased by 47.42% to ¥2,171,241,681.64 due to higher sales and the exclusion of Haizheng Borui from the consolidation scope[33]. - Prepayments rose by 79.91% to ¥289,424,298.89 primarily due to increased prepayments to Shanghai Baiying from Haizheng Borui's subsidiary not being consolidated[33]. - Other receivables surged by 2684.31% to ¥1,911,758,818.36 mainly due to the receivable from the equity transfer of Taima[33]. - The company reported an increase in undistributed profits to ¥2,482,274,124.98, up from ¥1,224,509,254.75, representing a growth of 102.5%[61].